Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

SLN: This study is testing the safety and effectiveness of different doses of a new treatment (called SLN124) in adults with Polycythemia VeraPhase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This study has two phases. Phase 1 is a dose-finding study. Participants enrolled in this part of the study will receive escalating doses of SLN124 which will be administered as an injection under the skin. Participants enrolled in Part 2 will be randomly allocated to receive either SLN124 or a placebo, both given via an injection under the skin.

Treatment Type

Systemic therapy (chemotherapy, hormone therapy or immunotherapy)

Age

People 18+

Phase

I/II

Trial Acronym

SLN

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT05499013
SLN124-004

Commercial Sponsor

Silence Therapeutics plc

Scientific Title

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy